Who Prioritizes Innovation? R&D Spending Compared for TG Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc.

Biotech R&D: Arrowhead vs. TG Therapeutics

__timestampArrowhead Pharmaceuticals, Inc.TG Therapeutics, Inc.
Wednesday, January 1, 20142313805031354781
Thursday, January 1, 20155741014743445817
Friday, January 1, 20164145445266489820
Sunday, January 1, 20173169029896886134
Monday, January 1, 201852968505153793000
Tuesday, January 1, 201981048686148369000
Wednesday, January 1, 2020128874979151934000
Friday, January 1, 2021206342000198532000
Saturday, January 1, 2022297307000112128000
Sunday, January 1, 202335318800076192000
Monday, January 1, 2024505870000
Loading chart...

In pursuit of knowledge

Innovation in Biotech: A Comparative Analysis

In the ever-evolving world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Arrowhead Pharmaceuticals, Inc. and TG Therapeutics, Inc. have demonstrated contrasting approaches to R&D investment.

From 2014 to 2023, Arrowhead Pharmaceuticals has consistently increased its R&D spending, culminating in a remarkable 2,085% growth by 2023. This upward trend underscores Arrowhead's dedication to pioneering new treatments and technologies. In contrast, TG Therapeutics showed a more fluctuating pattern, peaking in 2021 with a 533% increase from 2014, before experiencing a decline.

The data reveals Arrowhead's strategic focus on sustained innovation, while TG Therapeutics' variable investment may reflect a more adaptive approach to market demands. As the biotech landscape continues to shift, these spending patterns offer valuable insights into each company's long-term vision.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025